Discovery of Potent and Selective RSK Inhibitors as Biological Probes
Rama Jain, Cynthia M. Shafer(Novartis (Switzerland)), Stephen E. Basham(Therapeutics Clinical Research), Mika Lindvall, Savithri Ramurthy(FuelCell Energy (United States)), Michelle Mathur, Paul Feucht(Novartis (United States)), Gordana Atallah, B.A. Appleton(Novartis (Switzerland)), Jiong Lan(Novartis (Switzerland)), Sharadha Subramanian(Novartis (Switzerland)), Anne B. Jefferson, Abran Costales(Novartis (Switzerland)), Laura V. Doyle, L Setti, Bob Warne
Cited by 84
Related Papers
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
|Nature Communications|2019|213
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
|Clinical Cancer Research|2014|111
Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
|Molecular Cancer Research|2014|80